GlaxoSmithKline said Wednesday it has invested $120 million to expand its manufacturing facility in Upper Merion.
Emma Walmsley, CEO of GSK, said the "next generation" biopharmaceutical plant unites research and development and manufacturing in one location to "support and accelerate the transformation of our pipeline to deliver the next generation of medicines and vaccines for patients who need them."
Walmsley said the investment also underscores GSK’s "longstanding commitment to making innovative…
